Tumor Microenvironment and Immunotherapy-Based Approaches in Mantle Cell Lymphoma.
BAFF
BCR
Bcl2
Bruton’s tyrosine kinase
NF-kB
SOX11
mantle cell lymphoma
tumor microenvironment
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
30 Jun 2022
30 Jun 2022
Historique:
received:
12
05
2022
revised:
23
06
2022
accepted:
26
06
2022
entrez:
9
7
2022
pubmed:
10
7
2022
medline:
10
7
2022
Statut:
epublish
Résumé
Mantle cell lymphoma (MCL) is an aggressive B-cell non-Hodgkin lymphoma (NHL) characterized by the translocation t(11;14) (q13;q32) and a poor response to rituximab-anthracycline-based chemotherapy. High-dose cytarabine-based regimens offer a durable response, but an important number of MCL patients are not eligible for intensive treatment and are ideal candidates for novel targeted therapies (such as BTK, proteasome or BCL2 inhibitors, Immunomodulatory Drugs (IMiDs), bispecific antibodies, or CAR-T cell therapy). On the bench side, several studies aiming to integrate the tumor within its ecosystem highlighted a critical role of the tumor microenvironment (TME) in the expansion and resistance of MCL. This led to important insights into the role of the TME in the management of MCL, including potential targets and biomarkers. Indeed, targeted agents often have a combined mechanism of action on the tumor B cell but also on the tumor microenvironment. The aim of this review is to briefly describe the current knowledge on the biology of the TME in MCL and expose the results of the different therapeutic strategies integrating the TME in this disease.
Identifiants
pubmed: 35804999
pii: cancers14133229
doi: 10.3390/cancers14133229
pmc: PMC9265015
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Blood. 2012 Mar 1;119(9):1963-71
pubmed: 22210878
Br J Haematol. 2017 Nov;179(3):399-409
pubmed: 28771673
Blood. 2016 Dec 15;128(24):2808-2818
pubmed: 27697772
Leukemia. 2019 Oct;33(10):2442-2453
pubmed: 30940906
Nat Rev Clin Oncol. 2013 May;10(5):267-76
pubmed: 23546520
Immunol Rev. 2011 Nov;244(1):115-33
pubmed: 22017435
Leuk Lymphoma. 2019 Oct;60(10):2498-2507
pubmed: 30821551
Blood. 2021 Nov 4;138(18):1721-1726
pubmed: 34115836
Br J Haematol. 2020 May;189(4):684-688
pubmed: 32011729
Haematologica. 2012 Aug;97(8):1255-63
pubmed: 22371181
Haematologica. 2013 Sep;98(9):1458-66
pubmed: 23508008
Oncotarget. 2015 Apr 20;6(11):8750-9
pubmed: 25797245
Lancet. 2016 Feb 20;387(10020):770-8
pubmed: 26673811
Haematologica. 2018 Jan;103(1):116-125
pubmed: 29079592
Hum Pathol. 2005 Oct;36(10):1113-9
pubmed: 16226112
Leukemia. 2009 Jan;23(1):170-7
pubmed: 18843286
Blood. 2016 Sep 1;128(9):1226-33
pubmed: 27458004
J Clin Oncol. 2016 Aug 10;34(23):2698-704
pubmed: 27269947
J Clin Oncol. 2009 Feb 1;27(4):511-8
pubmed: 19075279
Lancet. 2018 Feb 17;391(10121):659-667
pubmed: 29241979
N Engl J Med. 2018 Mar 29;378(13):1211-1223
pubmed: 29590547
N Engl J Med. 2013 Aug 8;369(6):507-16
pubmed: 23782157
Clin Cancer Res. 2020 Aug 15;26(16):4216-4224
pubmed: 32461234
Blood Adv. 2021 Apr 27;5(8):2063-2074
pubmed: 33877296
J Clin Oncol. 2005 Aug 10;23(23):5347-56
pubmed: 15983389
Invest New Drugs. 2019 Apr;37(2):297-306
pubmed: 30132271
Cancer Cell. 2012 Jun 12;21(6):723-37
pubmed: 22698399
Eur J Immunol. 2007 Jan;37(1):110-8
pubmed: 17154264
J Clin Oncol. 2009 Aug 10;27(23):3822-9
pubmed: 19581539
Br J Haematol. 2013 Feb;160(4):487-502
pubmed: 23252516
Br J Haematol. 2015 Jul;170(1):131-4
pubmed: 25559624
Oncoimmunology. 2021 Mar 5;10(1):1893501
pubmed: 33747637
J Clin Oncol. 2006 Oct 20;24(30):4867-74
pubmed: 17001068
Blood Adv. 2019 Aug 27;3(16):2491-2498
pubmed: 31451445
Br J Haematol. 2021 May;193(3):520-531
pubmed: 33686666
Proc Natl Acad Sci U S A. 2013 Nov 5;110(45):18250-5
pubmed: 24145436
J Exp Med. 1999 Jun 7;189(11):1747-56
pubmed: 10359578
Cancer Cell. 2016 Nov 14;30(5):806-821
pubmed: 27846393
Haematologica. 2022 Mar 10;:
pubmed: 35263985
Blood. 2007 Sep 1;110(5):1631-8
pubmed: 17502456
N Engl J Med. 2018 Sep 6;379(10):934-947
pubmed: 30184451
Blood. 2010 Jun 3;115(22):4393-402
pubmed: 20194898
Blood. 2018 Nov 22;132(21):2249-2259
pubmed: 30254130
Biomark Res. 2021 May 26;9(1):38
pubmed: 34039409
Cancer Res. 2012 Oct 15;72(20):5307-16
pubmed: 22915760
Blood. 2020 Mar 26;135(13):996-1007
pubmed: 31977002
Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2352-7
pubmed: 16461462
Cancer. 2008 Aug 15;113(4):791-8
pubmed: 18615506
Clin Cancer Res. 2016 Jan 1;22(1):187-99
pubmed: 26350264
Semin Cancer Biol. 2011 Nov;21(5):308-12
pubmed: 21945516
J Clin Invest. 2022 Feb 1;132(3):
pubmed: 34882582
Int J Cancer. 2015 Jun 15;136(12):2761-74
pubmed: 25388373
Blood. 2009 May 7;113(19):4604-13
pubmed: 19228923
Front Oncol. 2019 Jan 07;8:645
pubmed: 30666297
Blood. 2016 Oct 6;128(14):1814-1820
pubmed: 27354719
Br J Haematol. 2014 Mar;164(6):811-21
pubmed: 24328678
J Clin Oncol. 2017 Mar 10;35(8):826-833
pubmed: 28095146
Br J Haematol. 2021 Oct;195(2):162-173
pubmed: 33783838
Clin Cancer Res. 2008 Jul 15;14(14):4650-7
pubmed: 18628480
Blood Adv. 2022 Feb 22;6(4):1350-1360
pubmed: 34662895
Blood. 2016 May 19;127(20):2375-90
pubmed: 26980727
Blood Cancer Discov. 2021 May;2(3):250-265
pubmed: 34027417
Clin Cancer Res. 2021 Aug 15;27(16):4652-4663
pubmed: 34158358
Blood. 2016 Jul 7;128(1):82-92
pubmed: 27127301
Transl Oncol. 2020 Mar;13(3):100744
pubmed: 32120334
Blood. 2013 Mar 21;121(12):2175-85
pubmed: 23321250
Nature. 2017 May 24;545(7655):423-431
pubmed: 28541315
Ann Oncol. 2013 Nov;24(11):2892-7
pubmed: 24030098
Lancet Oncol. 2012 Jul;13(7):716-23
pubmed: 22677155
Lancet. 2021 Sep 25;398(10306):1157-1169
pubmed: 34508654
N Engl J Med. 2014 Mar 20;370(12):1101-10
pubmed: 24401022
Blood. 2018 Nov 8;132(19):2016-2025
pubmed: 30181173
Blood. 2022 Feb 17;139(7):1026-1038
pubmed: 34496014
Blood. 2021 Dec 2;138(22):2202-2215
pubmed: 34189576
J Immunol. 2014 Mar 1;192(5):2252-60
pubmed: 24489098
Blood. 2021 Feb 18;137(7):877-887
pubmed: 33181832
Nat Med. 2019 Jan;25(1):119-129
pubmed: 30455436
Lancet Oncol. 2016 Mar;17(3):319-331
pubmed: 26899778
Oncotarget. 2017 Jun 13;8(24):39218-39229
pubmed: 28424405
Blood. 2021 Jan 14;137(2):216-231
pubmed: 33024998
Ann Oncol. 2017 Jul 1;28(suppl_4):iv62-iv71
pubmed: 28881919
Lancet Haematol. 2018 Mar;5(3):e109-e116
pubmed: 29396091
Blood. 2013 Oct 3;122(14):2412-24
pubmed: 23940282
Blood. 2020 Sep 17;136(12):1419-1432
pubmed: 32584970
Int J Mol Sci. 2021 Aug 09;22(16):
pubmed: 34445275
J Clin Oncol. 2016 Apr 1;34(10):1104-11
pubmed: 26884582
Blood. 2014 Sep 4;124(10):1637-44
pubmed: 24990888
J Clin Oncol. 2022 Feb 10;40(5):481-491
pubmed: 34914545
Int J Mol Sci. 2021 Jun 10;22(12):
pubmed: 34200679
Blood. 2014 Oct 2;124(14):2235-47
pubmed: 25092176
J Clin Oncol. 2013 Oct 10;31(29):3688-95
pubmed: 24002500
Nat Med. 2014 Jan;20(1):87-92
pubmed: 24362935
Blood Adv. 2022 Jun 14;6(11):3339-3342
pubmed: 35240689
Br J Cancer. 2011 Nov 22;105(11):1684-92
pubmed: 22045184
Blood. 2018 Jan 4;131(1):68-83
pubmed: 29118007
J Clin Invest. 2012 Oct;122(10):3416-23
pubmed: 23023712
Clin Cancer Res. 2018 Oct 1;24(19):4785-4797
pubmed: 29716920
Blood. 2017 Jul 27;130(4):501-513
pubmed: 28533307
Leukemia. 2000 Feb;14(2):292-8
pubmed: 10673747
Haematologica. 2009 Nov;94(11):1555-62
pubmed: 19880778
N Engl J Med. 2020 Apr 2;382(14):1331-1342
pubmed: 32242358